Search is Powered by Google
Breast Cancer News

Surveillance Mammography After Treatment For Primary Breast Cancer

Main Category: Breast Cancer
Also Included In: MRI / PET / Ultrasound
Article Date: 15 Sep 2008 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

The National Institute for Health Research Health Technology Assessment (NIHR HTA) programme has commissioned a new study to identify the most effective and efficient surveillance methods for women who have received treatment for primary breast cancer. There are 45,000 new cases in the UK each year and although the majority of women never experience a recurrence, it does return in approximately 25 per cent of women. The majority of these recurrences are found during the first three years after treatment.

It is generally accepted that early diagnosis is a key factor influencing survival from breast cancer, with an 81 per cent reduction in mortality compared with women who were identified with more advanced stages. A recurrence of breast cancer might be found either by physical examination or by mammography, a process which uses low-dose X-rays to examine the breast. There is, however, no general agreement as to the best way to monitor patients for recurrence or how often women should receive X-rays.

The study, lead by Professor Fiona Gilbert of the University of Aberdeen is re-examining the data from existing research studies as well as data from clinicians and hospitals to assess the potential for reducing mortality through earlier detection of breast cancer while also considering the potential harms. The project will also investigate the cost-effectiveness of using mammography on a regular basis to identify the most appropriate method and recurrence.

Professor Gilbert says, "The key factor is to identify the best method for mammographic surveillance for patients after breast cancer treatment. In addition, we aim to look at alternative methods over the next three years to ascertain the most effective procedure for aftercare treatment and to estimate the cost-effectiveness of alternative follow-up schemes. In time we hope this will lead to an improvement in survival of women through a more efficient monitoring system."

Helen Nikandrou
Assistant Programme Manager
(HTA Communications Division)

Health Technology Assessment (HTA) programme managed by the National Institute for Health Research (NIHR)

The NIHR HTA programme is managed by the NIHR Coordinating Centre for Health Technology Assessment (NCCHTA). The NCCHTA is part of the NIHR Evaluation, Trials and Studies Coordinating Centre (NETS-CC), based at the University of Southampton.

http://www.hta.ac.uk
http://www.soton.ac.uk


Personalized Homepage Weekly Newsletters Daily News Alerts
Opioid Induced Constipation ADHD Anxiety Asthma Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles All 'How To...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
Understanding And Treating Triple-Negative Breast Cancer
07 Jan 2009
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein. It is characterized by its unique molecular profile...


Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

Breast Cancer Treatment: Get Involved image Breast Cancer Treatment: Get Involved

Today, breast cancer patients may be treated by a multidisciplinary team of specialists, consisting of nurses, oncologists, surgeons, social workers, nutritionists and genetic counselors. However, patients, too, have a critical role in their treatment...

View more videos...